← Back to Search

Cytokine Therapy

Rezpegaldesleukin for Alopecia Areata

Phase 2
Recruiting
Research Sponsored by Nektar Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and weeks 12, 16, 20, 24, 28, 32, and 36

Summary

"This trial aims to study the effects of a drug called pegylated-recombinant-human interleukin-2 in adults with severe to very severe alopecia areata. The study will last

Who is the study for?
This clinical trial is for adults with severe to very severe alopecia areata. Participants must complete a screening, undergo treatment for 36 weeks, and participate in follow-up for another 24 weeks. Specific eligibility criteria details were not provided.
What is being tested?
The study tests Rezpegaldesleukin (Rezpeg), a form of pegylated-recombinant-human interleukin-2, against a placebo to see its effect on alopecia areata. It's randomized and double-blind, meaning neither the researchers nor participants know who gets the real treatment or placebo.
What are the potential side effects?
Potential side effects of Rezpegaldesleukin were not detailed in the information provided. Typically, side effects could range from mild reactions at injection sites to more significant immune-related responses due to its nature as an interleukin-2 therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and weeks 12, 16, 20, 24, 28, 32, and 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and weeks 12, 16, 20, 24, 28, 32, and 36 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36
Secondary study objectives
Percent change from baseline in SALT score
Proportion of patients achieving an absolute SALT score ≤ 10/20/30/50
Proportion of patients achieving improvement in Severity of Alopecia Tool (SALT) ≥ 50%/75%/90%

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low DoseExperimental Treatment1 Intervention
Rezpegaldesleukin Low Dose Every 2 weeks
Group II: High DoseExperimental Treatment1 Intervention
Rezpegaldesleukin High Dose Every 2 weeks
Group III: PlaceboPlacebo Group1 Intervention
Placebo Every 2 weeks

Find a Location

Who is running the clinical trial?

Nektar TherapeuticsLead Sponsor
58 Previous Clinical Trials
10,232 Total Patients Enrolled
Study DirectorStudy DirectorNektar Therapeutics
1,277 Previous Clinical Trials
499,250 Total Patients Enrolled
1 Trials studying Alopecia Areata
13 Patients Enrolled for Alopecia Areata
~47 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top